Log in

Menlo Therapeutics Stock Forecast, Price & News

+0.02 (+1.10 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $1.83
50-Day Range
MA: $1.54
52-Week Range
Now: $1.83
Volume7.15 million shs
Average Volume2.82 million shs
Market Capitalization$306.87 million
P/E RatioN/A
Dividend YieldN/A
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.
Read More
Menlo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.23 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MNLO



Sales & Book Value

Annual Sales$10.64 million
Book Value$2.81 per share


Net Income$-73,700,000.00


Market Cap$306.87 million
Next Earnings Date10/29/2020 (Estimated)
OptionableNot Optionable
+0.02 (+1.10 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

How has Menlo Therapeutics' stock price been impacted by COVID-19?

Menlo Therapeutics' stock was trading at $3.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MNLO shares have decreased by 44.5% and is now trading at $1.83.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Menlo Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Menlo Therapeutics

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Menlo Therapeutics

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc (NASDAQ:MNLO) issued its earnings results on Thursday, August, 6th. The company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.07.
View Menlo Therapeutics' earnings history

What price target have analysts set for MNLO?

5 analysts have issued 1-year price objectives for Menlo Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they anticipate Menlo Therapeutics' stock price to reach $5.40 in the next twelve months. This suggests a possible upside of 195.1% from the stock's current price.
View analysts' price targets for Menlo Therapeutics

Are investors shorting Menlo Therapeutics?

Menlo Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totaling 10,340,000 shares, an increase of 19.0% from the July 15th total of 8,690,000 shares. Based on an average trading volume of 4,970,000 shares, the short-interest ratio is presently 2.1 days.
View Menlo Therapeutics' Short Interest

Who are some of Menlo Therapeutics' key competitors?

What other stocks do shareholders of Menlo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), OrganiGram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), BioNano Genomics (BNGO), Pennsylvania R.E.I.T. (PEI), AEterna Zentaris (AEZS) and Gran Tierra Energy (GTE).

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the following people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 53)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 47)
  • Dr. Mary C. Spellman, Chief Medical Officer (Age 57)
  • Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 48)
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an IPO on Thursday, January 25th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities served as the underwriters for the IPO and JMP Securities was co-manager.

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

Who are Menlo Therapeutics' major shareholders?

Menlo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (13.64%), Healthcare Value Capital LLC (1.01%), Monashee Investment Management LLC (0.60%), Sofinnova Investments Inc. (0.43%), Orbimed Advisors LLC (0.35%) and Bank of America Corp DE (0.34%). Company insiders that own Menlo Therapeutics stock include Andrew Saik, David Domzalski and Perceptive Advisors Llc.
View institutional ownership trends for Menlo Therapeutics

Which institutional investors are selling Menlo Therapeutics stock?

MNLO stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC.
View insider buying and selling activity for Menlo Therapeutics

Which institutional investors are buying Menlo Therapeutics stock?

MNLO stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Monashee Investment Management LLC, Healthcare Value Capital LLC, Bank of America Corp DE, Schonfeld Strategic Advisors LLC, Tekla Capital Management LLC, Nuveen Asset Management LLC, and Psagot Investment House Ltd.. Company insiders that have bought Menlo Therapeutics stock in the last two years include Andrew Saik, David Domzalski, and Perceptive Advisors Llc.
View insider buying and selling activity for Menlo Therapeutics

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $1.83.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $306.87 million and generates $10.64 million in revenue each year. The company earns $-73,700,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis. Menlo Therapeutics employs 43 workers across the globe.

What is Menlo Therapeutics' official website?

The official website for Menlo Therapeutics is www.menlotherapeutics.com.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company can be reached via phone at 800-775-7936 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.